Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy
Open accessThe DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index.
Abstract
Radiotherapy is one of the most successful cancer therapies. Here the effect of irradiation on antigen presentation by MHC class I molecules was studied. Cell surface expression of MHC class I molecules was increased for many days in a radiation dose-dependent manner as a consequence of three responses. Initially, enhanced degradation of existing proteins occurred which resulted in an increased intracellular peptide pool. Subsequently, enhanced translation due to activation of the mammalian target of rapamycin pathway resulted in increased peptide production, antigen presentation, as well as cytotoxic T lymphocyte recognition of irradiated cells. In addition, novel proteins were made in response to gamma-irradiation, resulting in new peptides presented by MHC class I molecules, which were recognized by cytotoxic T cells. We show that immunotherapy is successful in eradicating a murine colon adenocarcinoma only when preceded by radiotherapy of the tumor tissue. Our findings indicate that directed radiotherapy can improve the efficacy of tumor immunotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“irradiation can also increase tumor antigenicity through enriching the pool of antigenic peptides”
From Hallmarks of response, resistance, and toxicity to immune checkpoint blockade (2021) · cites this paper as Reits et al., 2006
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
In silico prediction of protein-protein interactions in human macrophages
Souiai, O., Guerfali, F., Ben Miled, S., Brun, C., & Benkahla, A. (2014) · BMC Research Notes · doi:10.1186/1756-0500-7-157 · Cited by 10,803
Significance analysis of microarrays applied to the ionizing radiation response
Tusher, V. G., Tibshirani, R., & Chu, G. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.091062498 · Cited by 10,568
Phenotypic Analysis of Antigen-Specific T Lymphocytes
Altman, J. D., Moss, P. A. H., Goulder, P. J. R., Barouch, D. H., McHeyzer-Williams, M. G., Bell, J. I., McMichael, A. J., & Davis, M. M. (1996) · Science · doi:10.1126/science.274.5284.94 · Cited by 3,544 · cited 1×
“folding the HLA-A1 heavy chain with peptides CGI-51(206–215), MSH6(469–478), and F-box protein Fbl7(335–362) and human β2m as described (51).”
BackgroundDNA double-strand breaks: signaling, repair and the cancer connection
Khanna, K. K., & Jackson, S. P. (2001) · Nature Genetics · doi:10.1038/85798 · Cited by 2,455
Rapid degradation of a large fraction of newly synthesized proteins by proteasomes
Schubert, U., Antón, L. C., Gibbs, J., Norbury, C. C., Yewdell, J. W., & Bennink, J. R. (2000) · Nature · doi:10.1038/35008096 · Cited by 1,536
Error-Tolerant Identification of Peptides in Sequence Databases by Peptide Sequence Tags
Mann, M., & Wilm, M. (1994) · Analytical Chemistry · doi:10.1021/ac00096a002 · Cited by 1,468
Ionizing radiation inhibition of distant untreated tumors (abscopal effect) is immune mediated
Demaria, S., Ng, B., Devitt, M. L., Babb, J. S., Kawashima, N., Liebes, L., & Formenti, S. C. (2004) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2003.09.012 · Cited by 1,388
Fingar, D. C., & Blenis, J. (2004) · Oncogene · doi:10.1038/sj.onc.1207542 · Cited by 1,247
Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients
Lee, P. P., Yee, C., Savage, P. A., Fong, L., Brockstedt, D., Weber, J. S., Johnson, D., Swetter, S., Thompson, J., Greenberg, P. D., et al. (1999) · Nature Medicine · doi:10.1038/9525 · Cited by 1,113
Lugade, A. A., Moran, J. P., Gerber, S. A., Rose, R. C., Frelinger, J. G., & Lord, E. M. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.12.7516 · Cited by 966 · cited 3×
“This is probably not due only to up-regulation of MHC class I expression because mTOR activation will have more general eff ects on protein expression including up-regulation of Fas, ICAM-1 (38), and interferon expression (33, 34).”
Background
Research works printed but not linked: 5
- 2000, Oncology (Huntingt), 14, 741
- 1988, Nippon Igaku Hoshasen Gakkai Zasshi., 48, 1572
- 2000, Anticancer Res., 20, 3375
- 2002, Cancer Res., 62, 1462
- 1991, Cancer Res., 51, 3657
Cited by
Items 101–200 of 1,000
Immunomodulation by radiotherapy in tumour control and normal tissue toxicity
Cytlak, U. M., Dyer, D. P., Honeychurch, J., Williams, K. J., Travis, M. A., & Illidge, T. M. (2022) · Nature Reviews Immunology · doi:10.1038/s41577-021-00568-1 · Cited by 258
Baird, J. R., Friedman, D., Cottam, B., Dubensky, T. W., Kanne, D. B., Bambina, S., Bahjat, K., Crittenden, M. R., & Gough, M. J. (2016) · Cancer Research · doi:10.1158/0008-5472.can-14-3619 · Cited by 257
Treg depletion with a low-dose metronomic temozolomide regimen in a rat glioma model
Banissi, C., Ghiringhelli, F., Chen, L., & Carpentier, A. F. (2009) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-009-0671-1 · Cited by 255
Liu, Y., Crowe, W. N., Wang, L., Lu, Y., Petty, W. J., Habib, A. A., & Zhao, D. (2019) · Nature Communications · doi:10.1038/s41467-019-13094-5 · Cited by 254
Mladenov, E., Magin, S., Soni, A., & Iliakis, G. (2016) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2016.03.003 · Cited by 250
Origins, genetic landscape, and emerging therapies of small cell lung cancer
Semenova, E. A., Nagel, R., & Berns, A. (2015) · Genes & Development · doi:10.1101/gad.263145.115 · Cited by 250
PD-1/PD-L1 checkpoint inhibitors in advanced hepatocellular carcinoma immunotherapy
Li, Q., Han, J., Yang, Y., & Chen, Y. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1070961 · Cited by 246
Radiation effects on antitumor immune responses: current perspectives and challenges
Walle, T., Martinez Monge, R., Cerwenka, A., Ajona, D., Melero, I., & Lecanda, F. (2018) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834017742575 · Cited by 243
The thymic medulla: a unique microenvironment for intercellular self-antigen transfer
Koble, C., & Kyewski, B. (2009) · Journal of Experimental Medicine · doi:10.1084/jem.20082449 · Cited by 240
Prognostic and predictive biomarkers for immunotherapy in advanced renal cell carcinoma
Rosellini, M., Marchetti, A., Mollica, V., Rizzo, A., Santoni, M., & Massari, F. (2023) · Nature Reviews Urology · doi:10.1038/s41585-022-00676-0 · Cited by 240
Cancer immunotherapy: broadening the scope of targetable tumours
van den Bulk, J., Verdegaal, E. M., & de Miranda, N. F. (2018) · Open Biology · doi:10.1098/rsob.180037 · Cited by 240
Combinations of Immunotherapy and Radiation in Cancer Therapy
Vatner, R. E., Cooper, B. T., Vanpouille-Box, C., Demaria, S., & Formenti, S. C. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00325 · Cited by 240
Radiotherapy-exposed CD8+ and CD4+ neoantigens enhance tumor control
Lhuillier, C., Rudqvist, N.-P., Yamazaki, T., Zhang, T., Charpentier, M., Galluzzi, L., Dephoure, N., Clement, C. C., Santambrogio, L., Zhou, X. K., et al. (2021) · Journal of Clinical Investigation · doi:10.1172/jci138740 · Cited by 240
The intersection of radiotherapy and immunotherapy: Mechanisms and clinical implications
Spiotto, M., Fu, Y.-X., & Weichselbaum, R. R. (2016) · Science Immunology · doi:10.1126/sciimmunol.aag1266 · Cited by 239
Neoantigen identification strategies enable personalized immunotherapy in refractory solid tumors
Chen, F., Zou, Z., Du, J., Su, S., Shao, J., Meng, F., Yang, J., Xu, Q., Ding, N., Yang, Y., et al. (2019) · Journal of Clinical Investigation · doi:10.1172/jci99538 · Cited by 229
Chandra, R. A., Wilhite, T. J., Balboni, T. A., Alexander, B. M., Spektor, A., Ott, P. A., Ng, A. K., Hodi, F. S., & Schoenfeld, J. D. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1046028 · Cited by 229
Radiation-induced effects and the immune system in cancer
Kaur, P., & Asea, A. (2012) · Frontiers in Oncology · doi:10.3389/fonc.2012.00191 · Cited by 229
“With a murine colon adenocarcinoma model, Reits et al. (2006) showed that radiation enhances MHC class I expression and that anti-tumor immunotherapy with adoptive CTL cells is active only when preceded by RT (8–10 Gy) of the primary tumor.”
BackgroundSheng, H., Huang, Y., Xiao, Y., Zhu, Z., Shen, M., Zhou, P., Guo, Z., Wang, J., Wang, H., Dai, W., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000340 · Cited by 228
“11 14 However, other than simulative effect, radiation also has suppressive effect on the tumor environment.”
The Impact of Radiation-Induced DNA Damage on cGAS-STING-Mediated Immune Responses to Cancer
Storozynsky, Q., & Hitt, M. M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21228877 · Cited by 228
Gulley, J. L., Arlen, P. M., Tsang, K.-Y., Yokokawa, J., Palena, C., Poole, D. J., Remondo, C., Cereda, V., Jones, J. L., Pazdur, M. P., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0126 · Cited by 228
Self-citationTargeting MHC-I molecules for cancer: function, mechanism, and therapeutic prospects
Wu, X., Li, T., Jiang, R., Yang, X., Guo, H., & Yang, R. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01899-4 · Cited by 223
“Notably, MHC-I could be upregulated by radiation, which makes it possible to improve antigen presentation and increase the recognition capacity and cytotoxicity of T cells [149–152].”
BackgroundHarnessing the immune system in glioblastoma
Brown, N. F., Carter, T. J., Ottaviani, D., & Mulholland, P. (2018) · British Journal of Cancer · doi:10.1038/s41416-018-0258-8 · Cited by 223
Combining Immune Checkpoint Inhibitors With Conventional Cancer Therapy
Yan, Y., Kumar, A. B., Finnes, H., Markovic, S. N., Park, S., Dronca, R. S., & Dong, H. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01739 · Cited by 223
Haen, S. P., Löffler, M. W., Rammensee, H.-G., & Brossart, P. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0387-x · Cited by 222
Muroyama, Y., Nirschl, T. R., Kochel, C. M., Lopez-Bujanda, Z., Theodros, D., Mao, W., Carrera-Haro, M. A., Ghasemzadeh, A., Marciscano, A. E., Velarde, E., et al. (2017) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-17-0040 · Cited by 215
Analysis of Major Histocompatibility Complex (MHC) Immunopeptidomes Using Mass Spectrometry*
Caron, E., Kowalewski, D., Chiek Koh, C., Sturm, T., Schuster, H., & Aebersold, R. (2015) · Molecular & Cellular Proteomics · doi:10.1074/mcp.o115.052431 · Cited by 213
Buchwald, Z. S., Wynne, J., Nasti, T. H., Zhu, S., Mourad, W. F., Yan, W., Gupta, S., Khleif, S. N., & Khan, M. K. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00612 · Cited by 213
The Tumor Immune Contexture of Prostate Cancer
Vitkin, N., Nersesian, S., Siemens, D. R., & Koti, M. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00603 · Cited by 212
Future cancer research priorities in the USA: a Lancet Oncology Commission
Jaffee, E. M., Dang, C. V., Agus, D. B., Alexander, B. M., Anderson, K. C., Ashworth, A., Barker, A. D., Bastani, R., Bhatia, S., Bluestone, J. A., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30698-8 · Cited by 208
Dual blockade immunotherapy targeting PD-1/PD-L1 and CTLA-4 in lung cancer
Cheng, W., Kang, K., Zhao, A., & Wu, Y. (2024) · Journal of Hematology & Oncology · doi:10.1186/s13045-024-01581-2 · Cited by 204
Wrzesinski, C., Paulos, C. M., Gattinoni, L., Palmer, D. C., Kaiser, A., Yu, Z., Rosenberg, S. A., & Restifo, N. P. (2007) · Journal of Clinical Investigation · doi:10.1172/jci30414 · Cited by 202
The 6th R of Radiobiology: Reactivation of Anti-Tumor Immune Response
Boustani, J., Grapin, M., Laurent, P.-A., Apétoh, L., & Mirjolet, C. (2019) · Cancers · doi:10.3390/cancers11060860 · Cited by 199
Vendetti, F. P., Karukonda, P., Clump, D. A., Teo, T., Lalonde, R., Nugent, K., Ballew, M., Kiesel, B. F., Beumer, J. H., Sarkar, S. N., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci96519 · Cited by 198
Brix, N., Tiefenthaller, A., Anders, H., Belka, C., & Lauber, K. (2017) · Immunological Reviews · doi:10.1111/imr.12573 · Cited by 197
The therapeutic significance of mutational signatures from DNA repair deficiency in cancer
Ma, J., Setton, J., Lee, N. Y., Riaz, N., & Powell, S. N. (2018) · Nature Communications · doi:10.1038/s41467-018-05228-y · Cited by 195
Barriers to Radiation-Induced In Situ Tumor Vaccination
Wennerberg, E., Lhuillier, C., Vanpouille-Box, C., Pilones, K. A., García-Martínez, E., Rudqvist, N.-P., Formenti, S. C., & Demaria, S. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00229 · Cited by 194
Reprogramming the immunological microenvironment through radiation and targeting Axl
Aguilera, T. A., Rafat, M., Castellini, L., Shehade, H., Kariolis, M. S., Hui, A. B.-Y., Stehr, H., von Eyben, R., Jiang, D., Ellies, L. G., et al. (2016) · Nature Communications · doi:10.1038/ncomms13898 · Cited by 194
Chemotherapy and radiotherapy: Cryptic anticancer vaccines
Ma, Y., Kepp, O., Ghiringhelli, F., Apetoh, L., Aymeric, L., Locher, C., Tesniere, A., Martins, I., Ly, A., Haynes, N. M., et al. (2010) · Seminars in Immunology · doi:10.1016/j.smim.2010.03.001 · Cited by 193
Leidner, R., Crittenden, M., Young, K., Xiao, H., Wu, Y., Couey, M. A., Patel, A. A., Cheng, A. C., Watters, A. L., Bifulco, C., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002485 · Cited by 190
Donlon, N. E., Power, R., Hayes, C., Reynolds, J. V., & Lysaght, J. (2021) · Cancer Letters · doi:10.1016/j.canlet.2020.12.045 · Cited by 189
Dying cell clearance and its impact on the outcome of tumor radiotherapy
Lauber, K., Ernst, A., Orth, M., Herrmann, M., & Belka, C. (2012) · Frontiers in Oncology · doi:10.3389/fonc.2012.00116 · Cited by 187
Suppressing T cell motility induced by anti–CTLA-4 monotherapy improves antitumor effects
Ruocco, M. G., Pilones, K. A., Kawashima, N., Cammer, M., Huang, J., Babb, J. S., Liu, M., Formenti, S. C., Dustin, M. L., & Demaria, S. (2012) · Journal of Clinical Investigation · doi:10.1172/jci61931 · Cited by 187
Jin, M., Fang, J., Peng, J., Wang, X., Xing, P., Jia, K., Hu, J., Wang, D., Ding, Y., Wang, X., et al. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02176-8 · Cited by 189
Tumor-draining lymph node is important for a robust abscopal effect stimulated by radiotherapy
Buchwald, Z. S., Nasti, T. H., Lee, J., Eberhardt, C. S., Wieland, A., Im, S. J., Lawson, D., Curran, W., Ahmed, R., & Khan, M. K. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000867 · Cited by 183
Intratumoral Immunotherapy for Early-stage Solid Tumors
Hong, W. X., Haebe, S., Lee, A. S., Westphalen, C. B., Norton, J. A., Jiang, W., & Levy, R. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-3642 · Cited by 183
“For example, at certain dosages, radiotherapy not only eliminates tumor cells via DNA-damage and programmed cell death, but also elicits tumorspecific immune responses by tumor antigen release and activation of effector cells (43, 44, 46, 48).”
BackgroundDoes the mobilization of circulating tumour cells during cancer therapy cause metastasis?
Martin, O. A., Anderson, R. L., Narayan, K., & MacManus, M. P. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.128 · Cited by 182
Effects of conventional therapeutic interventions on the number and function of regulatory T cells
Roselli, M., Cereda, V., di Bari, M. G., Formica, V., Spila, A., Jochems, C., Farsaci, B., Donahue, R., Gulley, J. L., Schlom, J., et al. (2013) · OncoImmunology · doi:10.4161/onci.27025 · Cited by 182
Self-citationMolecular mechanisms of MHC class I abnormalities and APM components in human tumors
Seliger, B. (2008) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-008-0515-4 · Cited by 182
The Reciprocity between Radiotherapy and Cancer Immunotherapy
Wang, Y., Liu, Z.-G., Yuan, H., Deng, W., Li, J., Huang, Y., Kim, B. Y. S., Story, M. D., & Jiang, W. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-2581 · Cited by 181
Oncolytic viruses: a novel form of immunotherapy
Prestwich, R. J., Harrington, K. J., Pandha, H. S., Vile, R. G., Melcher, A. A., & Errington, F. (2008) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.8.10.1581 · Cited by 180
Frey, B., Rückert, M., Deloch, L., Rühle, P. F., Derer, A., Fietkau, R., & Gaipl, U. S. (2017) · Immunological Reviews · doi:10.1111/imr.12572 · Cited by 180
Angell, T. E., Lechner, M. G., Jang, J. K., LoPresti, J. S., & Epstein, A. L. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0879 · Cited by 152
Surace, L., Lysenko, V., Fontana, A. O., Cecconi, V., Janssen, H., Bicvic, A., Okoniewski, M., Pruschy, M., Dummer, R., Neefjes, J., et al. (2015) · Immunity · doi:10.1016/j.immuni.2015.03.009 · Cited by 179
“The stimulation of tumor-specific immunity by standard therapies including radio- and chemotherapy has been documented in several publications (Formenti and Demaria, 2012; Gupta et al., 2012; Matsumura et al., 2008; Reits et al., 2006; Sharma et al., 2013) and this phenomenonmight actually be of great clinical importa…”
BackgroundSelf-citationRadiation-induced bystander and abscopal effects: important lessons from preclinical models
Daguenet, E., Louati, S., Wozny, A.-S., Vial, N., Gras, M., Guy, J.-B., Vallard, A., Rodriguez-Lafrasse, C., & Magné, N. (2020) · British Journal of Cancer · doi:10.1038/s41416-020-0942-3 · Cited by 178
Current concepts in clinical radiation oncology
Orth, M., Lauber, K., Niyazi, M., Friedl, A. A., Li, M., Maihöfer, C., Schüttrumpf, L., Ernst, A., Niemöller, O. M., & Belka, C. (2014) · Radiation and Environmental Biophysics · doi:10.1007/s00411-013-0497-2 · Cited by 178
Chen, Y., Gao, M., Huang, Z., Yu, J., & Meng, X. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00940-z · Cited by 178
Immune Priming of the Tumor Microenvironment by Radiation
Jiang, W., Chan, C. K., Weissman, I. L., Kim, B. Y. S., & Hahn, S. M. (2016) · Trends in Cancer · doi:10.1016/j.trecan.2016.09.007 · Cited by 178
PD-1 and PD-L1 inhibitors in cold colorectal cancer: challenges and strategies
Lin, K. X., Istl, A. C., Quan, D., Skaro, A. I., Tang, E. S.-T., & Zheng, X. (2023) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-023-03520-5 · Cited by 179
In situ vaccination by radiotherapy to improve responses to anti-CTLA-4 treatment
Vanpouille-Box, C., Pilones, K. A., Wennerberg, E., Formenti, S. C., & Demaria, S. (2015) · Vaccine · doi:10.1016/j.vaccine.2015.05.105 · Cited by 177
The immune mechanisms of abscopal effect in radiation therapy
Grass, G. D., Krishna, N., & Kim, S. (2016) · Current Problems in Cancer · doi:10.1016/j.currproblcancer.2015.10.003 · Cited by 175
Effects of Chemotherapy on the Immune System: Implications for Cancer Treatment and Patient Outcomes
Sharma, A., Jasrotia, S., & Kumar, A. (2024) · Naunyn-Schmiedeberg's Archives of Pharmacology · doi:10.1007/s00210-023-02781-2 · Cited by 174
Radiotherapy–immunotherapy combinations – perspectives and challenges
Mondini, M., Levy, A., Meziani, L., Milliat, F., & Deutsch, E. (2020) · Molecular Oncology · doi:10.1002/1878-0261.12658 · Cited by 174
Role of T lymphocytes in tumor response to radiotherapy
Demaria, S., & Formenti, S. C. (2012) · Frontiers in Oncology · doi:10.3389/fonc.2012.00095 · Cited by 174
Mathematical Modeling of Cancer Immunotherapy and Its Synergy with Radiotherapy
Serre, R., Benzekry, S., Padovani, L., Meille, C., André, N., Ciccolini, J., Barlesi, F., Muracciole, X., & Barbolosi, D. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-3567 · Cited by 174
Rationale of combination of anti-PD-1/PD-L1 antibody therapy and radiotherapy for cancer treatment
Sato, H., Okonogi, N., & Nakano, T. (2020) · International Journal of Clinical Oncology · doi:10.1007/s10147-020-01666-1 · Cited by 173
Novel Approaches to Improve the Efficacy of Immuno-Radiotherapy
Shevtsov, M., Sato, H., Multhoff, G., & Shibata, A. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00156 · Cited by 173
Modern Radiotherapy Concepts and the Impact of Radiation on Immune Activation
Deloch, L., Derer, A., Hartmann, J., Frey, B., Fietkau, R., & Gaipl, U. S. (2016) · Frontiers in Oncology · doi:10.3389/fonc.2016.00141 · Cited by 176
Radiotherapy and immunotherapy: open questions and future strategies
Pointer, K. B., Pitroda, S. P., & Weichselbaum, R. R. (2021) · Trends in cancer · doi:10.1016/j.trecan.2021.10.003 · Cited by 173
Toward Precision Radiotherapy for Use with Immune Checkpoint Blockers
Vanpouille-Box, C., Formenti, S. C., & Demaria, S. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0037 · Cited by 171
The impact of host genetic variation on infection with HIV-1
McLaren, P. J., & Carrington, M. N. (2015) · Nature Immunology · doi:10.1038/ni.3147 · Cited by 170
Immune Checkpoint inhibitors: An introduction to the next‐generation cancer immunotherapy
Lee, L., Gupta, M., & Sahasranaman, S. (2016) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.591 · Cited by 148
Role of Radiation Therapy in Modulation of the Tumor Stroma and Microenvironment
Menon, H., Ramapriyan, R., Cushman, T. R., Verma, V., Kim, H. H., Schoenhals, J. E., Atalar, S. C., Selek, U., Chun, S. G., Chang, J. Y., et al. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00193 · Cited by 170
The Abscopal Effect: A Review of Pre-Clinical and Clinical Advances
Janopaul-Naylor, J. R., Shen, Y., Qian, D. C., & Buchwald, Z. S. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222011061 · Cited by 169
Tumor Burden and Immunotherapy: Impact on Immune Infiltration and Therapeutic Outcomes
Kim, S. I., Cassella, C. R., & Byrne, K. T. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2020.629722 · Cited by 168
Combination immunotherapy approaches
Drake, C. G. (2012) · Annals of Oncology · doi:10.1093/annonc/mds262 · Cited by 168
Intrinsic Resistance of Solid Tumors to Immune Checkpoint Blockade Therapy
Zhao, X., & Subramanian, S. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-2379 · Cited by 157
Miyauchi, S., Kim, S. S., Pang, J., Gold, K. A., Gutkind, J. S., Califano, J. A., Mell, L. K., Cohen, E. E. W., & Sharabi, A. B. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0871 · Cited by 168
The Confluence of Stereotactic Ablative Radiotherapy and Tumor Immunology
Finkelstein, S. E., Timmerman, R., McBride, W. H., Schaue, D., Hoffe, S. E., Mantz, C. A., & Wilson, G. D. (2011) · Clinical and Developmental Immunology · doi:10.1155/2011/439752 · Cited by 167
The Abscopal Effect of Radiation Therapy: What Is It and How Can We Use It in Breast Cancer?
Hu, Z. I., McArthur, H. L., & Ho, A. Y. (2017) · Current Breast Cancer Reports · doi:10.1007/s12609-017-0234-y · Cited by 166
Dantuma, N. P., Heinen, C., & Hoogstraten, D. (2009) · DNA repair · doi:10.1016/j.dnarep.2009.01.005 · Cited by 166
Radiation as an Immune Modulator
Burnette, B., & Weichselbaum, R. R. (2013) · Seminars in Radiation Oncology · doi:10.1016/j.semradonc.2013.05.009 · Cited by 165
Wargo, J. A., Reuben, A., Cooper, Z. A., Oh, K. S., & Sullivan, R. J. (2015) · Seminars in Oncology · doi:10.1053/j.seminoncol.2015.05.007 · Cited by 164
Current Approaches for Combination Therapy of Cancer: The Role of Immunogenic Cell Death
Asadzadeh, Z., Safarzadeh, E., Safaei, S., Baradaran, A., Mohammadi, A., Hajiasgharzadeh, K., Derakhshani, A., Argentiero, A., Silvestris, N., & Baradaran, B. (2020) · Cancers · doi:10.3390/cancers12041047 · Cited by 164
CAR-T cell combination therapy: the next revolution in cancer treatment
Al-Haideri, M., Tondok, S. B., Safa, S. H., maleki, A. H., Rostami, S., Jalil, A. T., Al-Gazally, M. E., Alsaikhan, F., Rizaev, J. A., Mohammad, T. A. M., et al. (2022) · Cancer Cell International · doi:10.1186/s12935-022-02778-6 · Cited by 163
Immune targets in the tumor microenvironment treated by radiotherapy
Ozpiskin, O. M., Zhang, L., & Li, J. J. (2019) · Theranostics · doi:10.7150/thno.32648 · Cited by 163
Xia, F., Wang, Y., Wang, H., Shen, L., Xiang, Z., Zhao, Y., Zhang, H., Wan, J., Zhang, H., Wang, Y., et al. (2024) · Journal of Clinical Oncology · doi:10.1200/jco.23.02261 · Cited by 163
The Impact of Radiation on the Tumor Microenvironment: Effect of Dose and Fractionation Schedules
Arnold, K. M., Flynn, N. J., Raben, A., Romak, L., Yu, Y., Dicker, A. P., Mourtada, F., & Sims-Mourtada, J. (2018) · Cancer Growth and Metastasis · doi:10.1177/1179064418761639 · Cited by 162
Immune-mediated mechanisms influencing the efficacy of anticancer therapies
Coffelt, S. B., & de Visser, K. E. (2015) · Trends in Immunology · doi:10.1016/j.it.2015.02.006 · Cited by 163
Morisada, M. V., Clavijo, P. E., Moore, E. C., Sun, L., Chamberlin, M. M., Waes, C. V., Hodge, J. W., Mitchell, J. B., Friedman, J., & Allen, C. T. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1395996 · Cited by 162
Self-citationMutational patterns in chemotherapy resistant muscle-invasive bladder cancer
Liu, D., Abbosh, P., Keliher, D., Reardon, B., Miao, D., Mouw, K., Weiner-Taylor, A., Wankowicz, S., Han, G., Teo, M. Y., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-02320-7 · Cited by 151
Rational combinations of immunotherapy with radiotherapy in ovarian cancer
Herrera, F. G., Irving, M. B., Kandalaft, L. E., & Coukos, G. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30401-2 · Cited by 162
Welsh, J. W., Tang, C. Z., de Groot, P. M., Naing, A., Hess, K. R., Heymach, J. V., Papadimitrakopoulou, V. A., Cushman, T. R., Subbiah, V., Chang, J. Y., et al. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0793 · Cited by 162
DRiPs solidify: progress in understanding endogenous MHC class I antigen processing
Yewdell, J. W. (2011) · Trends in Immunology · doi:10.1016/j.it.2011.08.001 · Cited by 161
Turning tumour cells into antigen presenting cells: The next step to improve cancer immunotherapy?
de Charette, M., Marabelle, A., & Houot, R. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2016.09.010 · Cited by 161
Niu, M., Liu, Y., Yi, M., Jiao, D., & Wu, K. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.827921 · Cited by 161
The immunocytokine NHS-IL12 as a potential cancer therapeutic
Fallon, J., Tighe, R., Kradjian, G., Guzman, W., Bernhardt, A., Neuteboom, B., Lan, Y., Sabzevari, H., Schlom, J., & Greiner, J. W. (2014) · Oncotarget · doi:10.18632/oncotarget.1853 · Cited by 160
Self-citationvan den Boorn, J. G., Picavet, D. I., van Swieten, P. F., van Veen, H. A., Konijnenberg, D., van Veelen, P. A., van Capel, T., de Jong, E. C., Reits, E. A., Drijfhout, J. W., et al. (2011) · Journal of Investigative Dermatology · doi:10.1038/jid.2011.16 · Cited by 160
Self-citationNanomedicine‐Boosting Tumor Immunogenicity for Enhanced Immunotherapy
Huang, J., Yang, B., Peng, Y., Huang, J., Wong, S. H. D., Bian, L., Zhu, K., Shuai, X., & Han, S. (2021) · Advanced Functional Materials · doi:10.1002/adfm.202011171 · Cited by 157
Radiation therapy-induced remodeling of the tumor immune microenvironment
Charpentier, M., Spada, S., Nest, S. J. V., & Demaria, S. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.04.003 · Cited by 159
Soluble PD-1: Predictive, Prognostic, and Therapeutic Value for Cancer Immunotherapy
Khan, M., Zhao, Z., Arooj, S., Fu, Y., & Liao, G. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.587460 · Cited by 158
Metadata
- Authors
- Reits, E. A., Hodge, J. W., Herberts, C. A., Groothuis, T. A., Chakraborty, M., K.Wansley, E., Camphausen, K., Luiten, R. M., de Ru, A. H., Neijssen, J., Griekspoor, A., Mesman, E., Verreck, F. A., Spits, H., Schlom, J., van Veelen, P., & Neefjes, J. J.
- Affiliations
- The Netherlands Cancer Institute (NL)
- 2Laboratory of Tumor Immunology and Biology
- National Institutes of Health (US)
- 4Department of Immunohematology and Blood Transfusion, Leiden University Medical Center, and Centre for Medical Systems Biology, 2333 2A Leiden, Netherlands
- Leiden University Medical Center (NL)
- ORCID
- Venue
- The Journal of Experimental Medicine
- Publisher
- Rockefeller University Press
- Published
- 2006-04-24
- Volume
- 203
- Issue
- 5
- Pages
- 1259-1271
- ISSN
- 0022-1007 (ISSN-L)
- 1540-9538
- PMC
- PMC3212727
- OpenAlex
- W2127733313
- Cited by
- 1,737
- References
- 53
- Citations by year
- 2026: 88 · 2025: 116 · 2024: 119 · 2023: 128 · 2022: 149 · 2021: 174 · 2020: 154 · 2019: 118 · 2018: 112 · 2017: 113 · 2016: 78 · 2015: 71 · 2014: 67 · 2013: 62 · 2012: 41
- FWCI
- 10.85
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Licence
- cc-by-nc-sa
- Locations
- The Journal of Experimental Medicine (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-sa)
- PubMed Central (publishedVersion, cc-by-nc-sa)
- PubMed (publishedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Pure Amsterdam UMC (submittedVersion)
- Funders
- National Institutes of Health
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Keywords
- radiotherapy, gamma irradiation, MHC class I expression, antigen presentation, protein degradation, mTOR signaling, translation (biology), cytotoxic T lymphocytes, cancer immunotherapy, colon adenocarcinoma
- MeSH terms
- Adenocarcinoma, Animals, Colonic Neoplasms, Dose-Response Relationship, Radiation, Gamma Rays, Humans, Immunotherapy, Mice, Transgenic, Peptides, Protein Kinases, Radiotherapy, T-Lymphocytes, Cytotoxic, Protein Biosynthesis, HLA-A2 Antigen, Gene Expression Regulation, Neoplastic, Antigen Presentation, Mice, TOR Serine-Threonine Kinases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.